Revenue

12 Months Ended

Dec. 29, 2019

Revenue from Contract with Customer [Abstract]

Revenue

2. REVENUE

Our revenue is generated primarily from the sale of products and services. Product revenue primarily consists of sales of instruments and consumables used in genetic analysis. Service and other revenue primarily consists of revenue generated from genotyping and sequencing services, instrument service contracts, and development and licensing agreements.

Revenue by Source

	2019						2018						2017
in millions	Sequencing		Microarray		Total		Sequencing		Microarray		Total		Sequencing		Microarray		Total
Consumables	$	2,075	$	317	$	2,392	$	1,824	$	353	$	2,177	$	1,484	$	287	$	1,771
Instruments	517		20		537		535		37		572		487		31		518
Total product revenue	2,592		337		2,929		2,359		390		2,749		1,971		318		2,289
Service and other revenue	476		138		614		416		168		584		322		141		463
Total revenue	$	3,068	$	475	$	3,543	$	2,775	$	558	$	3,333	$	2,293	$	459	$	2,752

Revenue by Geographic Area

Based on region of destination (in millions)	2019		2018		2017
Americas (1)	$	1,970	$	1,864	$	1,585
Europe, Middle East, and Africa	933		851		653
Greater China (2)	372		365		292
Asia-Pacific	268		253		222
Total revenue	$	3,543	$	3,333	$	2,752

(1) Revenue for the Americas region included United States revenue of $1,859 million, $1,779 million, and $1,511 million in 2019, 2018, and 2017, respectively.

(2) Region includes revenue from China, Taiwan, and Hong Kong.

Performance Obligations

We regularly enter into contracts with multiple performance obligations. Most performance obligations are generally satisfied within a short time frame, approximately three to six months, after the contract execution date. As of December 29, 2019, the aggregate amount of the transaction price allocated to remaining performance obligations was $980 million, of which approximately 66% is expected to be converted to revenue through 2020, approximately 14% in the following twelve months, and the remainder thereafter.

Contract Liabilities

Contract liabilities, which consist of deferred revenue and customer deposits, as of December 29, 2019 and December 30, 2018 were $209 million and $206 million, respectively, of which the short-term portions of $167 million and $175 million, respectively, were recorded in accrued liabilities and the remaining long-term portions were recorded in other long-term liabilities. Revenue recorded in 2019 included $150 million of previously deferred revenue that was included in contract liabilities as of December 30, 2018.